Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Total Debt
Short-term and long-term borrowings combined.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 117.1% from a year ago
Total debt stood at $202.87K at the end of Q1 FY2026, up 117.1% from a year earlier and down 57.2% from the prior quarter. Over 3 fiscal years it compounded at -6.6% a year.
Context
- Total debt amounted to 3.5% of total assets at the end of Q1 FY2026, down 15.5 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +117.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 473.75K USD
- Year-over-year change
- +407.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 473.75K | +407.1% |
| FY2024 | 2024-12-31 | 93.43K | -7.5% |
| FY2023 | 2023-12-31 | 101K | -82.6% |
| FY2022 | 2022-12-31 | 581.79K | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Debt vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 total debt of $202.87K is the 5th highest of the 6 companies compared; the peer median is $1.51M.
- Its year-over-year change of +117.1% is the 3rd highest of 6, against a peer median of +23.7%.
- Total debt amounts to 3.5% of total assets for TELO, versus a peer median of 5.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $230.87M | +23.7% | +9.3% | 175.7% | |
| Mar 2026 | $48.03M | -8.8% | -4.1% | 14.7% | |
| Mar 2026 | $1.51M | +335.2% | -59.3% | 5.8% | |
| Mar 2026 | $692K | +134.6% | -58.7% | 1.1% | |
| Mar 2026 | $202.87K | +117.1% | -6.6% | 3.5% | |
| Mar 2026 | $100K | -95.1% | -49.2% | 0.5% | |
| Peer median (excluding TELO) | $1.51M | +23.7% | -49.2% | 5.8% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.